Gilead Sciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GIS.F | GLAXO.BO | BMY | BIIB | SNY | GSK | |
|---|---|---|---|---|---|---|
| Market cap | 191.58B | 423.63B | 131.21B | 37.61B | 113.74B | 102.53B |
| P/E (TTM) | — | 44.4 | 14.2 | 110.2 | 23.6 | 17.8 |
| Forward P/E | — | 36.9 | 9.6 | 15.6 | 8.9 | 10.3 |
| Price/book | 16.5 | 24.8 | 5.6 | 2.0 | 1.4 | 4.1 |
| Dividend yield | 1.94% | 1.75% | 3.93% | — | 5.10% | 3.55% |
| 1-year change | +40.57% | +6.17% | +37.66% | +62.35% | −4.08% | +8.60% |
| Today | +0.89% | −1.26% | +4.02% | +2.22% | +4.72% | +5.03% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All GIS.F news ›Gilead Sciences, Inc. $GILD Stock: AIA Group Ltd Reduces Stake
MarketBeat Gilead Sciences, Inc. $GILD Stock: AIA Group Ltd Reduces Stake - AIA Group cut its Gilead stake by 17.9% in the third quarter, selling 7,132 shares and ending the period with 32,632 shares valued at about $4.9 million. Instit
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
- Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking technology with Gilead’s oncology development and commercialization expertise - This is the…
Gilead Sciences, Inc. $GILD Stock Purchased by Rakuten Investment Management Inc.
Get Our Latest Research Report on GILD The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be issued a dividend of $0.82 per share.…
Gilead Sciences, Inc. $GILD Stock Purchased by Provenance Wealth Advisors LLC
GILD stock opened at $167.47 on Wednesday. Gilead Sciences, Inc. has a 1-year low of $116.88 and a 1-year high of $175.65. The firm has a market cap of $207.72 billion, a P/E ratio of -53.00 and a beta of 0.35. The business's 50 day moving…
Gilead Sciences (GILD) Receives a Buy from Morgan Stanley
Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades. In a report released today, Terence Flynn from Morgan Stanley assigned a Buy rating to Gilead Sciences, with a price target…
Gilead Sciences (GILD) Receives a Rating Update from a Top Analyst
Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades. TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences today and set a price target of $175.00. Van…
DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167
www.marketscreener.com Published on 11/04/2026 at 05:37 am EST Gilead to Buy Cancer Biotech Tubulis in $5B Deal April 08, 2026 at 04:23 pm EDT
Gilead Sciences Announces Presentation of Late-Breaking Clinical Data and Real-World Evidence At Hiv Glasgow
Gilead Sciences announced its participation in the International Congress on Drug Therapy in HIV Infection , taking place from November 8-11. Results from more than 50 studies, including late-breaking...
Gilead Sciences declares $0.82 dividend
Gilead Sciences declares a $0.82 quarterly dividend with a 1.92% forward yield. - Gilead Sciences (GILD) declares $0.82/share quarterly dividend, in line with previous. - Payable Dec. 30; for shareholders of record Dec. 15; ex-div Dec. 15.
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com30
- marketbeat.com26
- theglobeandmail.com7
- defenseworld.net6
- seekingalpha.com6
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.